Drug Profile

Pumecitinib gel - Prime Gene Therapeutics

Alternative Names: PG-011

Latest Information Update: 06 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prime Gene Therapeutics
Class Anti-inflammatories; Antiallergics; Skin disorder therapies; Small molecules
Mechanism of Action Janus kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Mar 2025 Phase-II/III clinical trials in Allergic rhinitis in China (Intranasal) (NCT06837233) (Prime Gene Therapeutics pipeline, March 2025)
28 Feb 2025 Prime Gene Therapeutics plans a phase II trial in Allergic rhinitis in China (Intranasal, Spray) (NCT06837233)
16 Oct 2024 Phase-I clinical trials in Dermatitis (Topical), prior to October 2024 (Prime Gene Therapeutics pipeline, October 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com